March 2017

New Product - Hyqvia

Hyqvia (human normal immunoglobulin) is a human plasma derived immunoglobulin produced from large pools of human plasma by modified Cohn-Oncley cold ethanol fractionation, yielding an intermediate immunoglobulin G, referred to as precipitate G. Vorhyaluronidase alfa is used as a permeation enhancer, increasing permeability of the subcutaneous tissue by temporarily depolymerising hyaluronan. Hyqvia is indicated as replacement therapy in adults with primary immunodeficiency disease, and symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. Hyqvia is contraindicated in patients who have had a history of anaphylactic or severe systemic reactions to the administration of IgG; IgA deficient patients with antibodies to IgA and a history of hypersensitivity; and in patients with known systemic hypersensitivity to hyaluronidase or vorhyaluronidase alfa. Hyqvia is available as a single use vial containing immune globulin G (100 mg/mL) with another single use vial containing vorhyaluronidase alfa (160 units/mL) in packs of 1’s in the following strengths. 2.5 g/25 mL (vial + permeation enhancer 1.25 mL); 5 g/50 mL (vial + permeation enhancer 2.5 mL); 10 g/100 mL (vial + permeation enhancer 5 mL); 20 g/200 mL (vial + permeation enhancer 10 mL); and 30 g/300 mL (vial + permeation enhancer 15 mL).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629